Combination of CDH17 and CLDN18 covered 50 cases out of 56 (89.3%), which indicated that the coupling of markers for CDH17 and CLDN18 provides an opportunity to detect gastric cancer using specific antibodies. Here, CLDN18 is linked to gastric cancer.